Should glucagon-like peptide-1 receptor agonist treatment be withheld in preoperative management
Endocrinology 144: 5149-5158, 2003
By targeting natural pathways for glucose control and fat metabolism, they promote stable energy, endurance, and sustainable weight loss
doi: 10.3389/fnbeh.2026.1805953 Received 06 February 2026 Revised 13 March 2026 Accepted 13 March 2026 Published 13 April 2026 Volume 20 - 2026 Edited by Emmanuel Darcq, Institut National de la Sant et de la Recherche Mdicale (INSERM), France Reviewed by Zhe Zhao, Max Planck Florida Institute for Neuroscience (MPFI), United States Madhawi Aldhwayan, King Saud University, Saudi Arabia Updates Copyright 2026 OConnor
For individuals focused exclusively on type 2 diabetes management, Ozempic may be the preferred option due to its proven efficacy in enhancing glycemic control